# ProMIS Neurosciences, Inc. (PMN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $10.20 (+4.62%)

> ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing antibody therapies and therapeutic vaccines that selectively target toxic misfolded proteins in neurodegenerative diseases. Leveraging its proprietary platforms, ProMIS and Collective Coordinates algorithms—along with the advanced EpiSelect™ target discovery engine—the company identifies disease-specific epitopes on misfolded proteins to enable precision treatments. Its lead candidates include PMN310, a monoclonal antibody against toxic oligomers for Alzheimer’s disease; PMN267 for amyotrophic lateral sclerosis; and PMN442 for multiple system atrophy, with additional programs like PMN440 and PMN311 vaccines addressing synucleinopathies and amyloid-beta pathologies. ProMIS Neurosciences also advances therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. Founded in 2004 as Amorfix Life Sciences Ltd. and rebranded in 2015, the company operates from offices in Toronto, Ontario, Canada, and Cambridge, Massachusetts, USA, with a small team of eight employees led by CEO Neil Warma. Operating in the healthcare sector, ProMIS Neurosciences plays a pivotal role in precision medicine for misfolded protein disorders.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/PMN)